Search

Background: Chad with 7,698 confirmed cases of infection and 194 deaths since the beginning of the COVID-19 pandemic, is one of the African countries with the lowest reported case numbers. However, this figure likely underestimates the true spread of the virus due to the low rate of diagnosis. The high rate of asymptomatic infections reflects the reality of SARS-CoV-2 transmission in Chad. In this study, we estimated the seroprevalence and identified factors associated with SARS-CoV-2 infection., Methods: A cross-sectional study was conducted between September 2022 and February 2023. A total of 1,290 plasma samples were collected from outpatient attendees at Health Facilities located in 11 provinces of Chad and tested by ELISA method, for the presence of IgG antibodies to SARS-CoV2 nucleocapsid (N) protein. KoboToolbox was used to gather data from the participants and data were analyzed using STATA 16., Results: The overall seroprevalence was 83.0% [95% CI = 81.6%-85.5%], with variations between provinces, ranging from 99.2% [95% CI = 94.0%-100%] in Moundou (Southern Chad) to 46.8% [95% CI = 36.0% -57.1%] in Biltine (Eastern Chad). Factors associated with the seroprevalence included military occupation (OR = 0.37 CI [0.80-1.77] p = 0.025) and age group between 55-64 years (OR = 0.33 CI [0.15-0.72] p = 0.005). While, other factors, such as gender and age were not significantly associated with seroprevalence., Conclusion: Our results indicated that, the seroprevalence of COVID-19 in Chad is among the highest in Sub-Saharan Africa. These estimates could guide the response and public health policy decisions, enhancing the management of future outbreaks involving respiratory pathogens., Competing Interests: Declarations Ethics approval and consent to participate The study protocol was approved by the Chad National Bioethics Committee (CNBT) on 08 April 2022 under number: 011CMT/PC/PMT/MESRI/SG/CNBT/2022 and authorized by the Chad Ministry of Public Health under number: N°2326/CMT/PC/PMT/MSPSN/SE/SG/DGPC/DPERO/SRO/2022. The protocol was presented to 11 focal points including 10 provinces and N’Djamena selected for the study. Training sessions on the data collection tool were organized before the start of data and sample collection. An information sheet was given to each voluntary participant as well as the signature of informed consent and assent for minors. The informed consent was obtained from all participants involved. For adult participants (aged ≥ 16 years), informed consent was obtained directly from each individual. For minor participants (aged < 16 years), informed consent was obtained from parents or the legally authorized representative (LAR). In both cases, consent was obtained in accordance with the ethical guidelines established by the approving ethics committee. Each participant was assigned a unique code, and the data was handled confidentially. Consent for publication Not applicable. Competing interests The authors declare no competing interests., (© 2024. The Author(s).)